Showing results (301-310 of 969) with videos related to
Sort By:
Pageof 97
Cells|January 11, 2022
Strategies to Optimize Adherence in Patients with Mycosis FungoidesWarren H Chan, Daniel J Lewis, Madeleine Duvic, et al.The Journal of Dermatological Treatment|January 25, 2011
Medication use and associated health care outcomes and costs for patients with psoriasis in the United StatesHsien-Chang Lin, Pedro T Lucas, Steven R Feldman, et al.The Journal of Dermatological Treatment|May 16, 2020
Topical methotrexate in dermatology: a review of the literatureDivya Aickara, Arjun M Bashyam, Rita O Pichardo, et al.Journal of Cutaneous Medicine and Surgery|January 24, 2004
Terbinafine is more effective than itraconazole in treating toenail onychomycosis: results from a meta-analysis of randomized controlled trialsAlexander H Krob, Alan B Fleischer, Ralph D'Agostino, et al.Dermatology Online Journal|January 28, 2003
Pediatricians who prescribe clotrimazole-betamethasone diproprionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug's potencyDivya Railan, Jill K Wilson, Steven R Feldman, et al.Journal of the American Academy of Dermatology|September 27, 2003
Electronic monitoring of medication adherence in skin disease: results of a pilot studyRajesh Balkrishnan, Christie L Carroll, Fabian T Camacho, et al.Journal of the American Academy of Dermatology|September 27, 2003
Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States?Alan B Fleischer, Joanne K Simpson, Amy McMichael, et al.Managed Care Interface|February 4, 2006
Home ultraviolet B phototherapy: a cost-effective option for severe psoriasisChristopher B Yelverton, Amit S Kulkarni, Rajesh Balkrishnan, et al.Dermatology Online Journal|November 19, 2019
Contact dermatitis: one for the booksJennifer J Su, Wasim Haidari, Melissa B Hoffman, et al.The Journal of Dermatological Treatment|July 15, 2021
Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured populationChang Xu, Amanda Teeple, Bingcao Wu, et al.Pageof 97